Zacks Small-Cap Research

September 15, 2015

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

scr.zacks.com

10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606

Pharma-Bio Serv (PBSV-OTC)

PBSV: Revenue Returns to Sequential Growth, Solid EPS, Cash Flow. Reiterate Buy Rec

Current Recommendation	**Buy**
Prior Recommendation	N/A
Date of Last Change	09/15/2013
Current Price (09/15/15)	$1.00
Target Price	**$2.00**

OUTLOOK

Regularly recognized as one of the top validation companies in Puerto Rico, PBSV is principally engaged in providing compliance consulting to the pharmaceutical industry. Serving customers in the U.S., Europe, and Puerto Rico, PBSV counts many of the pharma "majors" as clients. The company's small size, high levels of expertise in various disciplines and reputation as an eminent life sciences consulting firm has allowed it to adapt to and capitalize on the changing regulatory landscape. This has fueled significant revenue growth and consistent history of profitability. While has slipped recently we attribute this mostly to macro-economic weakness and think PBSV returns to growth over the short-term. And despite revenue falling recently, cash flow generation has remained robust and the company remains highly profitable. Company has a stellar balance sheet with tons of cash which they are now looking to reinvest in the business. New catalysts emerging which could pay dividends in short-order.

SUMMARY DATA

52-Week High	**$1.40**
52-Week Low	**$0.83**
One-Year Return (%)	**-14.78**
Beta	**-0.31**
Average Daily Volume (sh)	**3,029**
Shares Outstanding (mil)	**23**
Market Capitalization ($mil)	**$23**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**43**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**22.3**
Earnings Per Share (%)	**29.3**
Dividend (%)	**N/A**
P/E using TTM EPS	**10.5**
P/E using 2015 Estimate	**15.0**
P/E using 2016 Estimate	**9.6**
Zacks Rank	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**Small-Value**
Industry	**Consulting**

ZACKS ESTIMATES

Revenue
(in millions)

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2014	$7.0 A	$6.6 A	$6.8 A	$7.1 A	$27.6 A
2015	$5.9 A	$5.4 A	$6.2 A	$6.3 E	$23.8 E
2016					$25.6 E
2017					$28.0 E

Earnings per Share

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2014	$0.03 A	$0.01 A	$0.03 A	$0.03 A	$0.10 A
2015	$0.01 A	$0.02 A	$0.02 A	$0.02 E	$0.07 E
2016					$0.10 E
2017					$0.16 E

Zacks Projected EPS Growth Rate - Next 4 Years % **18**

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

Fiscal Q3 2015 Results: *Revenue Returns to Sequential Growth, Churning Out Solid Net Income, EPS, Cash Flow…*

PBSV reported financial results for the fiscal third quarter ending July 31, 2015. While revenue slid on a y-o-y basis it jumped almost 14% sequentially and was well ahead of our estimate. The q-o-q growth and beat to our number was largely catalyzed by strength in the Puerto Rican consulting business - most of which (as has been the case recently) is attributable to projects in Latin America which are managed from Puerto Rico. And while fiscal Q3 marked the seventh consecutive quarter of y-o-y contraction (which has been attributed to delayed or cancelled projects resulting from the hangover in macro-economic weakness), the sequential sales growth may be indicative of a flattening or turn-around for the top-line as this is the first quarter since fiscal Q4 2014 that revenue has increased on a q-o-q basis. We continue to look for revenue in fiscal Q4 2015 (ending 10/31/2015) to increase from Q3 (although for it to be lower on a y-o-y basis).

And, importantly, the bottom-line remains well in the black, churning out almost $500k in net income in the most recent quarter and over $1M through the first nine months of fiscal 2015. In addition, the balance sheet remains solid ($14M in cash and no debt) and the shares trade at just barely above (1.05x) book value. With the Puerto Rican consulting business remaining robust, along with other potential catalysts that have recently come to light, as well as the opportunity that both the U.S. and European divisions stabilize, we continue to think that there are several reasons to believe revenue returns to growth in fiscal 2016 and beyond. This, coupled with the company's diligent focus on trimming costs as well as the ongoing share repurchase program, should bode well for EPS to return to growth in 2016 as well.

And there are other potential catalysts and contributors to revenue that we have yet to model - those being the possibility of near-term acquisitions (in December 2014 PBSV engaged a firm to explore M&A opportunities), the recently formed Calibrations division (expected to be partially operational by October 2015) and Pharma-Brazil, a newly registered wholly-owned subsidiary which will provide consulting services to the Brazilian market. Given the recent strength in Latin America-related project demand and revenue, this area of the world, including Brazil, could offer meaningful growth opportunity for PBSV.

Q3 revenue was $6.3 million, down 10% y-o-y but up about 14% from Q2 and 9% better than our $5.7 million estimate. As has been the case for the past several quarters, U.S. and European sales remained tepid, although both areas did experience growth on a sequential basis - this sequential growth could be a positive sign given that both territories have experienced sliding revenue on a q-o-q basis since at least fiscal Q3 2014 (ending July 2014).

U.S. sales in Q3 fell 60% y-o-y but grew 19% from Q2. If this is indeed the beginning of a trend towards continued sequential growth (although we think it is too early to assume as much), from the U.S. it would be a significant positive development as U.S. sales had only recently accounted for about 30% of total revenue but through the first nine months of fiscal 2015 accounted for less than 13% - which highlights the impact that this has had on the recent contraction in company-wide sales. Meanwhile, European sales also firmed up some in Q3. While down 49% y-o-y, they held better than steady on a q-o-q comparison, growing 10% from Q2. And while Europe, which accounts for only about 5% of total revenue, is not as meaningful as the U.S. or, nearly as important as Puerto Rico, firming up sales in that territory would be a bonus.

The Puerto Rican consulting business, most notably projects in Latin America managed in P.R., remain the highlight to both the top-line and contribution to operating income. P.R. consulting revenue jumped 19% y-o-y and was up more then 14% from Q3. Puerto Rico now accounts for approximately 83% of total sales, which is up from 61% through the first nine months of fiscal 2014. As we've noted in the past, this is meaningfully beneficial to net income as revenue generated in that territory is taxed at just 4% (as a result of the company's beneficial P.R. tax status), compared to a maximum regular federal income tax rate of 35% for U.S. operations. This is highlighted in the aggregate income tax rate, which fell from 18% in the first nine months of 2014 (when P.R. and U.S. revenue accounted for 61% and 31% of total sales, respectively) to just 9% in the first nine months of the current year (when P.R. and U.S. revenue accounted for 83% and 12% of total sales, respectively). So, the shift in geographic revenue mix essentially added almost $106k, or about 11% more to net income (so far) in the current year.

OpEx was $1.55 million, or 25% of revenue, which came in higher than our $1.30 million, or 23% of sales estimate. PBSV has been diligent on trimming costs where there are opportunities which has resulted in declining OpEx over the last few quarters. The recent tick up in Q3 was attributed, at least in part, to investments made in the under-development Calibrations Division (which is expected to be operational later this fiscal year).

Meanwhile gross margin was relatively beefy, coming in at 33.1% and the widest since fiscal Q1 2014 (ending Jan 31, 2014) - with recent strength attributed to higher testing volumes in the relatively high margin lab services business.

Q3 net income and EPS were $454k and $0.02, largely inline with our $409k and $0.02 estimates. Despite the y-o-y contraction in revenue over the last seven consecutive quarters PBSV continues to generate both positive net income and cash flow. Cash flow from operations (ex-changes in working capital) was $565k and $1.5 million in the first three and nine months of fiscal 2015. The company exited Q3 with $14 million in cash and securities.

Model Updates…
We have made only very minor updates to our model following Q3, none of which affect our outlook, recommendation or price target. We continue to model fiscal Q4 2015 revenue of $6.3 million, implying full year revenue of $23.8 million (-14% y-o-y). Our 2015 EPS estimate remains unchanged at $0.07).

PBSV first noted in their Q2 10-Q that they are "downsizing" their Integratek business (IT services and consulting based in P.R.) and indicating that this is being done in order to save costs. This division was mostly insignificant from a revenue standpoint so a reduction or shuttering of its operations should have no meaningful impact to sales but has the potential to trim the total expense base even further.

And recently three potential new catalysts emerged, none of which we currently model and all of which could provide upside to our estimates. One relates to the relationship with T.R. Winston which was announced in early December. The company has not talked specifics (only noting this is aimed mostly at the U.S. consulting business) but the fact that the balance sheet is frothing with cash, which continues to grow, and PBSV has entered into a relationship with a strategy and investment banking company leads us to believe that they are looking to reinvest their cash in growth opportunities. We have no insight into what types of opportunities that they may be exploring or potential timing but the possibility of an acquisition or partnership adds further to the potential that revenue turns back positive in the mid-term.

The other new potential catalyst is PBSV's Puerto Rican Calibrations Services Division. In October 2014 the company signed a collaboration agreement with Quality Technical Iberica, a Spain-based company specializing in calibrations, validation, HVAC and clean room qualification services. Iberica will assist the company in establishing a calibrations division that will provide calibration and related services in Puerto Rico. This, per the Q3 10-Q, is expected to be partially operational by the end of the current fiscal year (i.e. – October 31, 2015).

And the third and most recent addition is the formation of Pharma-Brazil, which was registered as a wholly-owned subsidiary of the company in April 2015. Pharma-Brazil will provide consulting services to that market - no timelines were offered on expectations of when this division will commence activity. The relative strength in revenue coming from Latin American markets may be a harbinger of the potential that Brazil may hold. This will be something to keep an eye on.

SERVICES

PBSV's core business is FDA and international agencies regulatory compliance and related services, although they also offer other integrated services that affords them the ability to be a full-service solution provider.

The vast majority of the company's services are provided through time and materials contracts where clients are charged for the time, materials and expenses incurred on a particular project or service. Time and material contracts, which account for approximately 92% of the company's revenue, have somewhat of a built-in margin to PBSV.

Compliance Consulting
PBSV has over 20 years of compliance consulting experience. Their consulting business caters to some of the largest life sciences organizations in the world including eight of the top ten pharmaceutical companies and seven of the top ten medical technology companies. The company believes their competitive advantages relative to compliance consulting include their two decades of experience, ability to offer a wide range and depth of services with very high levels of expertise, accomplished track record of exceptional performance that consistently meets

or exceeds client's expectations, and being able to provide their services at a significantly lower cost. PBSV also puts considerable effort into maintaining close and trusting relationships with their client companies, which provides clear benefits in terms of repeat business. Compliance consulting services accounts for approximately 92% of the company's total revenue.

PBSV's compliance consulting spans a large menu of services under a variety categories.

Scienza Labs

Per the company's website and company filings, Scienza Labs is a state of the art microbiological testing facility with the latest equipment and technology and test methodologies available, harmonized with the current pharmacopeias. The labs are designed to exceed customers' expectations with an excellent organization, on time delivery, and shorter testing cycle times. The lab provides services to the company's core industry (life sciences) as well as to the cosmetic and food industries. Microbiology and chemical testing services accounts for approximately 7% of the company's total revenue.

> State of the Art New Facilities with fully Validated Equipment

> FDA Registered and compliant with current regulations. Inspected by SJ District Office with zero observations

> ISO 9001:2008 Certified

> Certified Minority Controlled Company

> Excellent Organization

> On-Site Pick-up 24 hours a day / 7 days a week

> On time delivery



SOURCE: pharmabioserv.com

Integratek

Per the company's website and company filings, Integratek, their Puerto Rico based information technology services and consulting division, provides a variety of information technology services such as web pages and portals development, digital art design, intranets, extranets, software development including database integration, Windows and web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others. Integratek is a Microsoft Certified Partner and a reseller for technology products from leading vendors in the market. IT services and the company's Pharma Serv Academy (technical training) account for less than 1% of PBSV's total revenue. The company recently noted that they will downsize this business in order to cut costs.

> Application Development / Systems Integration
> Art Design / Web Pages and Portals
> Document Digitalization / Process Automation
> Networking / Help Desk / Virtualization
> E-Learning / Learning Mngmt Systems / Classroom & Webinar Courses
> Mobile Application Development
> Computer System Validation
> Project Management
> Systems Integration
> Temporary Staffing Services

Pharma Serv Academy

Pharma Serv Academy (per company filings and website), through a network of leading industry professional experts in their field, including those from PBSV, provides technical seminars/training that incorporate the latest regulatory trends and standards as well as other related areas. These services are provided in the markets that PBSV currently serves, as well as other industries.

> **Project Management**
> **Risk Management Program**
> **Regulatory Guidance Documents**
> **Regulatory Enforcement**
> **ICH Guidelines for Product Life Cycle**
> **Computer Systems**
> **Validation Courses**
> **Safety**
> **cGMPs**
> **Microbiology**
> **Quality Systems**
> **Other Seminars**
> **Lean Six Sigma / Process Excellence and Continuous Improvement Series**

FINANCIAL CONDITION / FINANCIAL PERFORMANCE

Solid, Spotless Balance Sheet and Significant Positive Cash Flow
PBSV maintains a stellar balance sheet, which is particularly impressive for a micro-cap company. At the most recent quarter-end (July 31, 2015) cash balance stood at $14 million. The company has zero debt, zero preferred stock, and about 23 million fully-diluted common shares outstanding. Quality of assets appears to be strong with an immaterial amount of intangibles, cash and securities accounting for about 61% of total assets, and no indication that all of A/R is anything other than collectible.

PBSV also has a history of positive cash flow generation. Cash flow from operating activities was $2.1 million in fiscal 2011, $2.5 million in fiscal 2012, $5.6 million in fiscal 2013 and $3.3 in 2014. The business is also not very capital intensive, with CapEx of just $123k in 2011, $169k in 2012, $205k in 2013 and $208k in 2014.

Recent Softness Not Expected To Be a Long-Term Trend. Cash Flow Continues…
While revenue and EPS contracted in 2014, PBSV continues to generate positive cash flow and maintains an ultra-healthy balance sheet.

2014 was a disappointing year in terms of revenue, falling 17% and no quarter doing better than an 8% yoy decrease. But "disappointing" should be put in context – PBSV grew revenue 76% in 2011, 47% in 2012 and 13% in 2013. And on top of that the company has been profitable every quarter since at least Q1 2011 – including every quarter in the relatively disappointing year of 2014 and through the first nine months of 2015. And on top of that, the company has consistently generated positive cash flow – including $3 million worth in relatively disappointing 2014 as well as $1.5 million in the first nine months of 2015.

But, back to the drop in revenue in 2014….while we think part of the difficulty has been the heavy reliance on just a small handful of customers contributing the bulk of business, more macro factors also played a big part. PBSV experienced a lag from the dive in the economy over the last few years with pharma clients either cancelling or delaying certain projects. We think there may be a continuing hangover through the remainder of the current year. But, with cost-control and gross margins holding up nicely, coupled with the fact that lower U.S. contribution benefits the average effective tax rate, we think the impact to the bottom line will be quite muted. And with the economic picture looking much brighter over the past few quarters, we expect the lag that PBSV felt following the downturn will result in a similar but opposite effect going into 2016.

And recently three potential new catalysts emerged, none of which we currently model and all of which could provide upside to our estimates. One relates to the relationship with T.R. Winston which was announced in early December. The company has not talked specifics (only noting this is aimed mostly at the U.S. consulting business) but the fact that the balance sheet is frothing with cash, which continues to grow, and PBSV has entered into a relationship with a strategy and investment banking company leads us to believe that they are looking to reinvest their cash in growth opportunities. We have no insight into what types of opportunities that they may be exploring or potential timing but the possibility of an acquisition or partnership adds further to the potential that revenue turns back positive in the mid-term.

The other new potential catalyst is PBSV's Puerto Rican Calibrations Services Division. In October 2014 the company signed a collaboration agreement with Quality Technical Iberica, a Spain-based company specializing in calibrations, validation, HVAC and clean room qualification services. Iberica will assist the company in establishing a calibrations division that will provide calibration and related services in Puerto Rico. This, per the Q3 10-Q, is expected to be partially operational by the end of the current fiscal year (i.e. – October 31, 2015).

And the third and most recent addition is the formation of Pharma-Brazil, which was registered as a wholly-owned subsidiary of the company in April 2015. Pharma-Brazil will provide consulting services to that market - no timelines were offered on expectations of when this division will commence activity. The relative strength in revenue coming from Latin American markets may be a harbinger of the potential that Brazil may hold. This will be something to keep an eye on.

Beneficial Income Tax Status…

One somewhat unique advantage that PBSV enjoys and helps maximize the amount of revenue that flows to the bottom line is that they are subject to a lower than normal statutory Puerto Rico income tax rate. In June 2011 the company obtained a Grant of Industrial Tax Exemption from the Puerto Rico Industrial Development Company. The grant was effective November 2009. The grant provides relief on various Puerto Rico taxes, including income tax, with certain limitations, for most of the activities carried on within Puerto Rico, including those that are for services to parties located outside of Puerto Rico. The grant, which is effective through 2024, significantly reduces PBSV's Puerto Rico income tax liability from what would have been a tax rate of 30% (which increased to 39% in fiscal 2014) to what was an effective rate of 5.5% in fiscal 2011, 5.4% in 2012 and 4% in 2013 and 2014 (and should remain at 4% until expiration).

This grant only covers operations in Puerto Rico. Operations carried out in the United States are taxed at a maximum regular federal income tax rate of 35%.

PBSV's total effective tax rate in 2012, 2013 and 2014 were 18.6%, 19.3% and 16.2% which is significantly favorable relative to the 35% U.S. federal statutory rate and PBSV's 2010 effective rate of 40.1% (which was prior to obtaining the grant). And so while the recent softness in U.S. revenue has been a disappointment, as U.S. revenue falls as a % of total revenue, the company's overall effective tax rate will also fall which mutes the impact of sliding revenue to the bottom line.

Valuation / Recommendation

Based on our model we look for EPS to grow at a 4-year CAGR of about 18% through 2018. We use an industry PE/G ratio of 1.6x to value PBSV. We look for 2015 EPS of $0.07 (unchanged since our prior update) which values the company at approximately $2.00/share (also unchanged since our last update). The stock currently trades at about $1.00, indicating the shares are trading cheaper than fair value.

We also note that book value (as of July 31, 2015) is $21.5 million or only about 1.05x of current market value – which should provide a fairly solid floor on the stock price. And given PBSV's long history of cash flow generation, which has continued during the recent slide in revenue, we think it is reasonable to expect book value to continue to grow, raising this floor and further reducing any downside risk. We recommend accumulating up to our $2.00/share price target. We are maintaining our But rating.

FINANCIAL MODEL

Pharma-Bio Serv, Inc

	2014 A	Q1A	Q2A	Q3A	Q4E	2015 E	2016 E	2017 E	2018 E
Total Revenues	$27,555.0	$5,882.2	$5,442.7	$6,182.0	$6,333.4	$23,840.2	$25,620.3	$27,999.7	$29,690.5
YOY Growth	*-16.7%*	*-16.1%*	*-17.2%*	*-9.6%*	*-11.2%*	*-13.5%*	*7.5%*	*9.3%*	*6.0%*
Cost of Services	$18,581.9	$4,176.9	$3,756.6	$4,135.7	$4,300.4	$16,369.6	$17,268.1	$18,451.8	$19,298.8
Gross Income	$8,973.1	$1,705.3	$1,686.0	$2,046.2	$2,033.0	$7,470.6	$8,352.2	$9,547.9	$10,391.7
Gross Margin	*32.6%*	*29.0%*	*31.0%*	*33.1%*	*32.1%*	*31.3%*	*32.6%*	*34.1%*	*35.0%*
SG&A	$6,109.1	$1,376.9	$1,294.0	$1,550.9	$1,482.0	$5,703.8	$5,713.3	$5,739.9	$5,849.0
% SG&A	*22.2%*	*23.4%*	*23.8%*	*25.1%*	*23.4%*	*23.9%*	*22.3%*	*20.5%*	*19.7%*
Operating Income	$2,864.1	$328.4	$392.0	$495.3	$551.0	$1,766.8	$2,638.9	$3,808.0	$4,542.7
Operating Margin	*10.4%*	*5.6%*	*7.2%*	*8.0%*	*8.7%*	*7.4%*	*10.3%*	*13.6%*	*15.3%*
Total Other Income (Expense)	($1.8)	($1.2)	($0.8)	($0.2)	($1.0)	($3.2)	$6.0	$8.0	$22.0
Pre-Tax Income	$2,862.3	$327.2	$391.2	$495.1	$550.0	$1,763.6	$2,644.9	$3,816.0	$4,564.7
Tax expense (benefit)	$464.5	$38.8	$32.2	$41.1	$46.8	$158.9	$283.0	$461.7	$584.3
Tax Rate	*16.2%*	*11.9%*	*8.2%*	*8.3%*	*8.5%*	*9.0%*	*10.7%*	*12.1%*	*12.8%*
Net Income	$2,397.7	$288.4	$359.0	$454.0	$503.3	$1,604.6	$2,361.9	$3,354.2	$3,980.4
YOY Growth	*-51.1%*	*-56.4%*	*9.5%*	*-24.0%*	*-37.9%*	*-33.1%*	*47.2%*	*42.0%*	*18.7%*
Net Margin	*8.7%*	*4.9%*	*6.6%*	*7.3%*	*7.9%*	*6.7%*	*9.2%*	*12.0%*	*13.4%*
EPS	$0.10	$0.01	$0.02	$0.02	$0.02	$0.07	$0.10	$0.16	$0.19
YOY Growth	*-51.2%*	*-55.9%*	*11.2%*	*-23.1%*	*-36.4%*	*-32.0%*	*52.0%*	*49.3%*	*19.2%*
Diluted Shares O/S	23,695	23,464	23,428	23,355	23,100	23,337	22,600	21,500	21,400

Brian Marckx, CFA

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

BALANCE SHEET

	July 31, 2015	October 31, 2014
ASSETS		
Current assets:		
Cash and cash equivalents	$ 14,008	$ 15,088
Marketable Securities	34	68
Accounts Receivable	7,680	6,386
Other	872	783
Total current assets	22,595	22,325
Property and equipment, net	697	869
Other assets	20	17
Total assets	$ 23,312	$ 23,211
LIABILITIES		
Current liabilities:		
Current portion-obligations under capital lease	$ 22	$ 22
Accounts payable and accrued expenses	1,492	2,355
Income taxes payable	238	249
Total current liabilities	1,753	2,626
Obligations under capital leases	57,782	75
Total liabilites	1,810	2,700
STOCKHOLDERS' EQUITY		
Preferred Stock	-	-
Common stock	2	2
Additional paid-in capital	1,163	1,055
Retained earnings	20,708	19,607
Accumulated other comprehensive loss	(226,592)	(136)
Total stockholders' equity	21,502	20,511
Total liabilities and stockholders' equity	$ 23,312	$ 23,211

CASH FLOW STATEMENT

	Three months July 31, 2015	2014
Cash flows from operating activities:		
Net income	$ 454	597
Adjustments to reconcile net income to net cash provided by operating activities:		
Gain on disposition of P&E	-	-
Stock-based compensation	21	17
Depreciation and amortization	90	94
Changes in operating assets and liabilities:		
Accounts receivable	(579)	632
Other assets	(115)	(96)
Liabilities	(220)	(148)
Net cash provided by operating activities	(349)	1,096
Cash flows from investing activities:		
Acquisition of P&E	(33)	(106)
Proceeds from disposition of P&E	-	-
Net cash used in investing activities	(33)	(106)
Cash flows from financing activities:		
Proceeds from common stock issuance	-	-
Repurchase of common stock	(8)	(2)
Payments on obligations under capital lease	(5)	(10)
Net cash provided by (used in) financing activities	(14)	(13)
Effect of exchange rate changes on cash	(2)	(9)
Net increase (decrease) in cash and cash equivalents	(398)	968
Cash and cash equivalents, beginning of period	14,405	12,829
Cash and cash equivalents, end of period	$ 14.007.856	13,797

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brian Marckx, CFA, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1165 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 23.4%, Hold/Neutral- 60.1%, Sell/Underperform – 13.5%. Data is as of midnight on the business day immediately prior to this publication.